FIELD: medicine.
SUBSTANCE: what is presented is an antibody characterised by the fact that it binds the human p40 IL-12 subunit and comprises six CDR regions (CDR1, CDR2, CDR3 from the light chain and CDR1, CDR2, CDR3 from heavy chain). There are described: an antibody construct, an antibody conjugate, versions of coding nucleic acid, versions of vectors (for expression and replication), versions of a host cell, a method for producing the antibody, versions of compositions, versions of a method of treating an individual having unfavourable IL-12 activity, a method of reducing IL-12 activity in a human.
EFFECT: use of the invention can find application in medicine for prevention and treatment of acute and chronic diseases associated with activity of the human p40 subunit.
115 cl, 24 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS OF TREATING PSORIASIS | 2008 |
|
RU2475265C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
METHOD OF TREATING PSORIASIS (VERSIONS) | 2009 |
|
RU2497545C2 |
NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
Authors
Dates
2012-09-20—Published
2006-06-29—Filed